Prioritization for Rational Use of Antirheumatic Drugs: Strategic Development for Sustainable Health Policies

Year 2026, Volume: 30 Issue: 2, 693 - 702, 15.03.2026

Yaşar Gökalp , Serkan Eti , Sefer Aygün , Yeter Uslu , Selenay Koç

https://doi.org/10.12991/jrespharm.1706294

https://izlik.org/JA23WG79UY

Abstract

Consumption of antirheumatic drugs is known to be very high. It is important to support the rational use of these drugs. In this context, the study aims to develop a prioritized strategy to ensure rational consumption of antirheumatic drugs. Accordingly, a literature-based criteria set is created, and a 3-stage analysis is performed. In the first stage, Taxicab distance-based clustering analysis is performed for expert selection. The entropy method is used to weight the identified criteria. It is seen that the most important criterion is lifestyle factor (w=0,37). The alternative analysis for this criterion is performed with the ARAS method. Both methods are integrated with Fermatean fuzzy numbers to minimize uncertainty. The results of the alternative analysis show that the most optimal strategies are increasing physical activity (w=0,94) and healthy dietary practices (w=0,78). There is a need to encourage individuals taking antirheumatic drugs to engage in aerobic exercise and healthy eating.

Keywords

Rational drug use , antirheumatic drug , sustainable healthcare , ARAS , entropy

Ethical Statement

Ethical approval was not required for this study, as it did not involve human participants, animal subjects, personal data collection, or any procedures requiring ethical oversight.

References

• [1] İlaç Endüstrisi İşverenler Sendikası. Dünya ve Türkiye İlaç Pazarı. Accessed: 10 Mart 2025. https://www.ieis.org.tr/tr/dunya-ve-turkiye-ilac-pazari.
• [2] Dong Y, Yang T, Xing Y, Du J, Meng Q. Data-driven modeling methods and techniques for pharmaceutical processes. Processes. 2023;11(7):2096. https://doi.org/10.3390/pr11072096
• [3] Fernández-Ávila DG, Betancur M, Kronfly A, Jáuregui E. Exploring drug utilization patterns, healthcare resource utilization, and epidemiology of rheumatoid arthritis in Colombia: a retrospective claims database study. BMC Rheumatol. 2025;9(1):13. https://doi.org/10.1186/s41927-025-00389-2
• [4] Karlsson ML, Klareskog L, Giuseppe DD, Chatzidionysiou K, EIRA Study Group. POS0439-HPR Pattern of lifestyle habits in patients with rheumatoid arthritis. Ann Rheum Dis. 2024;83:504-505.
• [5] Renard D, Tuffet S, Dieudé P, Claudepierre P, Gossec L, Fautrel B, et al. Factors associated with dietary practices and beliefs on food of patients with rheumatic and musculoskeletal diseases: a multicentre cross-sectional study. Joint Bone Spine. 2025;92(1):105778. https://doi.org/10.1016/j.jbspin.2024.105778
• [6] Li J, Baker R, Stovall R, Curtis JR, Xie F, Yazdany J, Schmajuk G. Agreement of medication information derived from EHR data compared to medicare insurance claims: an analysis of biologic disease‐modifying antirheumatic drugs. Pharmacoepidemiol Drug Saf. 2024;33(10):e70020. https://doi.org/10.1002/pds.5735
• [7] Martins A, Oliveira D, Nicolau R, Rocha TM, Bernardo A, Costa L, et al. What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs? Clin Rheumatol. 2024;43(1):251-258. https://doi.org/10.1007/s10067-023-06763-8
• [8] Shahidullah M, Khan MMKU, Talukder MLH, Akter T. Exploring the relationship between vitamin D deficiency and disease activity in rheumatoid arthritis patients. SAS J Med. 2024;10:1253-1258. https://doi.org/10.36347/sasjm.2024.v10i10.048
• [9] Sharma SD, Bluett J. Towards personalized medicine in rheumatoid arthritis. Open Access Rheumatol Res Rev. 2024;16:89-114.
• [10] Song F, Nakatani H, Sugiyama E, Hirata S. Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2024;34(3):479-487.
• [11] Walrabenstein W, Wagenaar C, Van der Leeden M, Turkstra F, Twisk J, Boers M, et al. AB0396 effect of a multidisciplinary lifestyle program in patients with rheumatoid arthritis: the plants for joints randomized controlled trial. Ann Rheum Dis. 2022;81:1326-1327.
• [12] Wagenaar CA, Walrabenstein W, Van Der Leeden M, Turkstra F, Gerritsen M, Twisk JW, et al. Long-term effectiveness of a lifestyle intervention for rheumatoid arthritis and osteoarthritis: 1-year follow-up of the ‘Plants for Joints’ randomised clinical trial. RMD Open. 2024a;10(1):e004025.
• [13] Lin J, Liu J, O’Fee A, Pandey C, Benna-Doyle S, Maunder A, et al. The effectiveness and safety of lifestyle medicine and integrative therapies in inflammatory arthritis: an umbrella review using a hierarchical evidence gathering approach. Front Med. 2024;11:1357914. https://doi.org/10.3389/fmed.2024.1357914
• [14] Wagenaar C, Walrabenstein W, Van der Leeden M, Gerritsen M, Twisk JWR, Van der Esch M, et al. OP0217 Long-Term Effectiveness of a Lifestyle Intervention for Osteoarthritis: Two-Year Follow-Up After the “Plants For Joints” Randomized Clinical Trial. Ann Rheum Dis. 2024b;83:118-119.
• [15] Liu Z, Tian M, Duan L. Letter to the editor regarding: “Incidence of malignancies and the association with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis: A time-dependent analysis from the IORRA patient registry”. Rheumatol Ther. 2025;1-3.
• [16] Smolen JS, Landewé RB, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
• [17] Ferrara F, Zovi A, Langella R, Trama U, Nava E, Comentale F, et al. Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority. Expert Rev Pharmacoecon Outcomes Res. 2025;25(2):227-233.
• [18] Bali O, Singla S. Cost of illness and out-of-pocket expenditure of ankylosing spondylitis and rheumatoid arthritis at a tertiary care hospital in North India using conventional disease-modifying antirheumatic drugs. Indian J Rheumatol. 2024;19(3):170-183. https://doi.org/10.1177/09733698241239709
• [19] Chan SJ, Stamp LK, Treharne GJ, Cheung JM, Dalbeth N, Grainger R, et al. Preferences for tapering biologic disease‐modifying antirheumatic drugs among people with rheumatoid arthritis: A discrete choice experiment. Arthritis Care Res. 2024. https://doi.org/10.1002/acr.25379
• [20] Mushtaq I, Rashid A, Majeed A, Riaz I, Baig ZA, Javaid A. Association of serum IL12 with clinical and biochemical parameters in a cohort of diagnosed rheumatoid arthritis patients on oral conventional synthetic disease-modifying anti-rheumatic drugs. J Pak Med Assoc. 2024;74(2):310-310.
• [21] Shakeel L, Shaukat A, Khaliq N, Kashif A, Mujeeb A, Adnan Z, et al. Rheumatoid arthritis: a comprehensive overview of genetic markers, emerging therapies, and personalized medicine. Ann Med Surg. 2025;85:10-1097.
• [22] Waldenlind K, Delcoigne B, Saevarsdottir S, Askling J. Disease‐modifying antirheumatic drugs and risk of thyroxine‐treated autoimmune thyroid disease in patients with rheumatoid arthritis. J Intern Med. 2024;295(3):313-321.
• [23] Altuntas, G, Yildirim, B, F. (2022). Logistics specialist selection with intuitionistic fuzzy TOPSIS method. International Journal of Logistics Systems and Management, 42(1), 1-34.
• [24] Karstensen JK, Bremander A, Christensen JR, Primdahl J. Participation in cardiovascular screening consultations, the who, when and why–A cohort study on patients with rheumatoid arthritis. BMC Rheumatol. 2024;8(1):8. https://doi.org/10.1186/s41927-024-00378-7
• [25] Toro-Gutiérrez CE, Arbeláez-Cortés Á, Fernández-Aldana AR, Mejía-Romero RA, Patarroyo PM, Quintana G, et al. Clinical practice guidelines for the early detection, diagnosis, treatment, and follow-up of patients with rheumatoid arthritis. Colombian Association of Rheumatology, 2022. Rev Colomb Reumatol (Engl Ed). 2024;31(2):205-222.
• [26] Singh G, Kumar V. Sleep quality is poor in rheumatoid arthritis patients and correlates with anxiety, depression, and poor quality of life. Mediterr J Rheumatol. 2024;35(3):423.
• [27] Fedorchenko Y, Mahmudov K, Abenov Z, Zimba O, Yessirkepov M. Rehabilitation of patients with inflammatory rheumatic diseases and comorbidities: unmet needs. Rheumatol Int. 2024;44(4):583-591.
• [28] Kaló Z, Vokó Z, Östör A, Clifton-Brown E, Vasilescu R, Battersby A, Gibson E. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5(1):1345580. https://doi.org/10.1080/20016689.2017.1345580
• [29] Ingrasciotta Y, Jin Y, Foti SS, Landon JE, Tari M, Mattace-Raso F, Trifirò G. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study. Clin Rheumatol. 2023;42(4):1047-1059.
• [30] Thompson C, Micic D. Nutrition and diet for patients with rheumatic disease. In: Interdisciplinary Rheumatology. CRC Press; 2025. p. 87-104.
• [31] Dehkordi MF, Hatefi SM, Tamošaitienė J. An integrated fuzzy Shannon Entropy and fuzzy ARAS model using risk indicators for water resources management under uncertainty. Sustainability. 2025;17(11):5108. https://doi.org/10.3390/su17115108
• [32] Natarajan E, Augustin F, Kalaiselvan S, Narayanamoorthy S, Samy CA, Ranganathan S, Ahmadian A. Enhancing healthcare accessibility for tuberculosis prevention: a bipolar fuzzy ARAS decision-making approach. In: The Prediction of Future Pandemics. Elsevier; 2025. p. 311-327. https://doi.org/10.1016/B978-0-443-22895-2.00022-5